Atomoxetine Hydrochloride + placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

ADHD

Conditions

ADHD

Trial Timeline

Sep 1, 2004 → Sep 1, 2006

NCT ID

NCT00190736

About Atomoxetine Hydrochloride + placebo

Atomoxetine Hydrochloride + placebo is a approved stage product being developed by Eli Lilly for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT00190736. Target conditions include ADHD.

What happened to similar drugs?

9 of 20 similar drugs in ADHD were approved

Approved (9) Terminated (3) Active (10)

✅atomoxetineEli LillyApproved

✅Strattera (atomoxetine)Eli LillyApproved

✅Atomoxetine + placeboEli LillyApproved

✅atomoxetine (Strattera)Eli LillyApproved

🔄dasotraline + PlaceboSumitomo PharmaPhase 3

🔄dasotraline 4mgSumitomo PharmaPhase 3

🔄Focalin XRNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00700427	Phase 3	Completed	Jun 1, 2008	Oct 1, 2013	Attention Deficit Hyperactivity Disorder
NCT00510276	Approved	Completed	Aug 1, 2007	Feb 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00190879	Approved	Completed	Jun 1, 2005	May 1, 2007	Attention Deficit Hyperactivity Disorder
NCT00191945	Phase 3	Completed	May 1, 2005	Feb 1, 2008	Attention Deficit Hyperactivity Disorder
NCT00191906	Approved	Completed	Apr 1, 2005	Dec 1, 2007	Attention Deficit Hyperactivity Disorder
NCT00190775	Approved	Completed	Sep 1, 2004	Oct 1, 2009	Attention Deficit Hyperactivity Disorder
NCT00190736	Approved	Completed	Sep 1, 2004	Sep 1, 2006	ADHD
NCT00485459	Phase 3	Completed	Feb 1, 2004	Nov 1, 2004	Attention Deficit Hyperactivity Disorder
NCT00191698	Phase 3	Completed	Dec 1, 2003	Nov 1, 2007	Attention Deficit Hyperactivity Disorder
NCT00190931	Approved	Completed	Nov 1, 2003	Jul 1, 2005	Attention Deficit Disorder With Hyperactivity
NCT00191009	Phase 2/3	Completed	Oct 1, 2003	Jan 1, 2006	Alzheimer Disease
NCT00486122	Approved	Completed	Sep 1, 2003	Jun 1, 2004	Attention Deficit Hyperactivity Disorder

Competing Products

20 competing products in ADHD

See all competitors

Product	Company	Stage	Hype Score
atomoxetine	Eli Lilly	Approved	39
Strattera (atomoxetine)	Eli Lilly	Approved	43
Atomoxetine + placebo	Eli Lilly	Approved	43
atomoxetine (Strattera)	Eli Lilly	Approved	43
Atomoxetine + stimulants (any approved ADHD medication)	Eli Lilly	Pre-clinical	26
dasotraline + Placebo	Sumitomo Pharma	Phase 3	40
dasotraline	Sumitomo Pharma	Phase 1	29
dasotraline 4mg	Sumitomo Pharma	Phase 3	40
AZD1446 + AZD1446 + AZD1446 + Placebo	AstraZeneca	Phase 2	35
Placebo + AZD3480 + AZD3480	AstraZeneca	Phase 2	35
MK0249 + Concerta (methylphenidate) + Placebo	Merck	Phase 2	35
Focalin XR	Novartis	Phase 3	40
Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo	Novartis	Approved	43
Dexmethylphenidate HCl extended-release capsules	Novartis	Phase 3	40
Methylphenidate hydrochloride	Novartis	Phase 3	40
Focalin XR	Novartis	Phase 3	40
methylphenidate HCl ERCT + Placebo	Pfizer	Approved	35
methylphenidate HCl ERCT	Pfizer	Approved	35
Very Low Dose Quillivant XR + Low Dose Quillivant XR + Moderate Dose Quillivant XR	Pfizer	Approved	43
Brexpiprazole	Lundbeck	Phase 1	26